Is neoadjuvant endocrine therapy (NET) an alternative treatment for neoadjuvant chemotherapy (NACT) in patients with invasive ductal carcinoma (IDC) of the breast who have strong hormone receptor (HR) positivity and human epidermal growth factor receptor 2 (ERBB2) negativity? The gene discussed is ERBB2; the disease is invasive ductal breast carcinoma.